New-onset atrial fibrillation detected by ambulatory ECG monitoring after transcatheter aortic valve implantation
EuroIntervention · 2024
DOI: 10.4244/eij-d-23-01014 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift EuroIntervention, 2024. Verfasst von Jorge Nuche und 9 weiteren Autor:innen. Beteiligte Einrichtung: Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada. Hauptthemen laut MEDLINE: Atrial Fibrillation, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Electrocardiography, Ambulatory. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Little is known about the occurrence of subclinical new-onset atrial fibrillation (NOAF) after transcatheter aortic valve implantation (TAVI). AIMS: We aimed to evaluate the incidence, predictors, and clinical impact of subclinical NOAF after TAVI. METHODS: This was a multicentre study, including patients with aortic stenosis (AS) and no previous atrial fibrillation undergoing TAVI, with continuous ambulatory electrocardiogram (AECG) monitoring after TAVI. RESULTS: A total of 700 patients (79±8 years, 49% female, Society of Thoracic Surgeons score 2.9% [1.9-4.0]) undergoing transarterial TAVI were included (85% balloon-expandable valves). AECG was started 1 (0-1) day after TAVI (monitoring time: 14 12 13 14 days). NOAF was detected in 49 patients (7%), with a median duration of 185 (43-421) minutes (atrial fibrillation burden of 0.7% [0.3-2.8]). Anticoagulation was started in 25 NOAF patients (51%). No differences were found in baseline or procedural characteristics, except for a higher AS severity in the NOAF group (peak gradient: no NOAF: 71.9±23.5 mmHg vs NOAF: 85.2±23.8 mmHg; p=0.024; mean gradient: no NOAF: 44.4±14.7 mmHg vs NOAF: 53.8±16.8 mmHg; p=0.004). In the multivariable analysis, the baseline mean transaortic gradient was associated with a higher risk of NOAF after TAVI (odds ratio 1.04, 95% confidence interval: 1.01-1.06 for each mmHg; p=0.006). There were no differences between groups in all-cause mortality (no NOAF: 4.7% vs NOAF: 0%; p=0.122), stroke (no NOAF: 1.4% vs NOAF: 2.0%; p=0.723), or bleeding (no NOAF: 1.9% vs NOAF: 4.1%; p=0.288) from the 30-day to 1-year follow-up. CONCLUSIONS: NOAF detected with AECG occurred in 7% of TAVI recipients and was associated with a higher AS severity. NOAF detection determined the start of anticoagulation therapy in about half of the patients, and it was not associated with an increased risk of clinical events at 1-year follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada.
- Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
- McMaster University, Hamilton, ON, Canada and Hamilton Health Sciences, Hamilton, ON, Canada.
- Division of Cardiology, Emory University, Atlanta, GA, USA.
- Clínic Barcelona, Barcelona, Spain.
Zitieren
APA
Nuche, J., Soliman, F., Chavarría, J., Okoh, A. K., Alvarado Mora, H., Nault, I., Natarajan, M. K., Russo, M., Philippon, F., & Rodés-Cabau, J. (2024). New-onset atrial fibrillation detected by ambulatory ECG monitoring after transcatheter aortic valve implantation. EuroIntervention. https://doi.org/10.4244/eij-d-23-01014
Vancouver
Nuche J, Soliman F, Chavarría J, Okoh AK, Alvarado Mora H, Nault I, et al. New-onset atrial fibrillation detected by ambulatory ECG monitoring after transcatheter aortic valve implantation. EuroIntervention. 2024. doi:10.4244/eij-d-23-01014
BibTeX
@article{Nuche2024,
author = {Nuche, Jorge and Soliman, Fady and Chavarría, Jorge and Okoh, Alexis K and Alvarado Mora, Hugo and Nault, Isabelle and Natarajan, Madhu K and Russo, Mark and Philippon, François and Rodés-Cabau, Josep},
title = {New-onset atrial fibrillation detected by ambulatory ECG monitoring after transcatheter aortic valve implantation},
journal = {EuroIntervention},
year = {2024},
doi = {10.4244/eij-d-23-01014}
}
EUVIMED